No treatment with chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, or other thiazolidinediones (TZDs) =< days before study registration Concurrent use of any other anti-cancer therapy, including chemotherapy, targeted therapy, immunotherapy, or biological agents Immunotherapy or biological therapy, or investigational agent within weeks (Note: some cohort exceptions allow anti-PD- therapy) Patients who have had chemotherapy or biological therapy within weeks of registration Prior systemic therapy: patients must be at least weeks from prior chemotherapy, biological agents, immunotherapy or any investigational drug product, with adequate recovery of toxicity Have not been treated with chemotherapy, biological therapy or breast radiotherapy Receipt of any chemotherapy, biological therapy or investigational agents within weeks prior to study registration Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy Receipt of any biological therapy, chemotherapy, or radiation within week of the Screening Visit and at least weeks prior to Day , except for patients receiving maintenance trastuzumab. Within days before first dose of protocol-indicated treatment:\r\n* Anti-cancer treatment including chemotherapy, radiation, hormonal therapy, targeted therapy, immunotherapy, or biological therapy\r\n* Major surgery requiring general anesthesia; (Note: within this time frame, placement of a central line or portacath is acceptable and does not exclude)\r\n* Receipt of an investigational agent DONOR: Receiving any investigational agents, or concurrent biological, chemotherapy, immunosuppression or radiation therapy Fewer than days from prior anticancer therapy including chemotherapy, hormonal, investigational, and/or biological therapies and irradiation except for: Prior biological cancer therapy, targeted therapy, or major surgery within days prior to first dose of therapy Subjects must be >= weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents; or at least half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation. Patient who has had chemotherapy, radiation, hormonal, or biological cancer therapy within days prior to the first dose of study drug Patients must be >= weeks beyond previous treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field; patients who have received non-chemotherapeutic biological agents will need to wait at least half-lives or weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy Patients may not be receiving any other investigational agents, or concurrent parenteral biological, chemotherapy, or radiation therapy; oral chemotherapeutic agents or biologics - for example ruxolitinib therapy (either past or current exposure) - is allowed Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Concurrent or planned use of any other anti-cancer systemic chemotherapy, biological therapy (including hormonal or immune therapy), radiation therapy, or live cancer vaccines Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy Is currently receiving active treatment with anti-cancer systemic chemotherapy, investigational agent, or biological therapy The subject has participated or is currently participating in another study of an investigational medicine or medical device (radiotherapy, radio-immunotherapy, biological therapy, chemotherapy), within -weeks prior to screening. Have had palliative radiation or biological cancer therapy within weeks prior to the first dose of study drug Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; may have received an experimental agent prior to enrolling in the trial Plans during the trial to receive any other (non-trial) investigational agents, or concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white blood count control is permitted) PHASE I and II -- Administration of any antineoplastic therapy within at least weeks (cytotoxic chemotherapy) or weeks (biological and targeted therapy; hypomethylating agents are considered to be biological therapy) of that therapy of the first MEK /MEK dose; except the use of hydroxyurea which can be administered up to g/day up to hours before the initiation of the study drug Patient who has had chemotherapy, radiation, hormonal, or biological cancer therapy < weeks prior to the first dose of study drug Chemotherapy, radiation, or biological or targeted therapy within weeks Patients must be >= weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field; patients who have received non-chemotherapeutic biological agents will need to wait at least half-lives or weeks (wks), whichever is shorter, from the last day of treatment; continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotropin-releasing hormone [GnRH] agonist), ovarian, or breast cancer are not exclusionary Plans for the patient to receive other concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol except at disease progression Patients receiving cytotoxic therapy (including endocrine and biological agents), radiation therapy, immunotherapy or non-topical steroids, within three () to four () weeks of enrollment. Has received chemotherapy (except hydroxyurea), biological therapy, radiotherapy or investigational therapy within weeks before baseline (CD). Patients who have received topical therapy, systemic chemotherapy, or biological therapy within weeks prior to registration are NOT eligible for participation Subjects must be >= weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents (>= weeks from previous bevacizumab treatment) at the time of first dose of study drug(s) At least weeks have passed since prior chemotherapy, biological therapy, radiation therapy, major surgery, other investigational or anti-cancer therapy that is considered disease-directed Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Patient is receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Patients are receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, biological therapy and hormonal therapy) while taking study medication Front-line treatment may include maintenance therapy following complete clinical or pathological response; however, maintenance cytotoxic chemotherapy must be discontinued for a minimum of months prior to documentation of recurrent disease; patients receiving maintenance biological therapy or hormonal therapy are ELIGIBLE provided their recurrence is documented more than months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum weeks has elapsed since their last infusion of biological therapy Would receive study treatment within weeks from radiation therapy, experimental therapy, hormonal therapy, prior chemotherapy, or biological therapy; use an invasive investigational device; or is currently enrolled in an investigational study Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within days prior to beginning study therapy. Patients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiation therapy, hormonal therapy, and biological therapy) while taking study medication or have previously received talimogene laherparepvec or any other oncolytic virus Patients must not have plans to receive concomitant chemotherapy, other biological or immune therapies, or radiation therapy for the treatment of prostate cancer during the period of study treatment Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for anti-cancer purposes, targeted therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within days prior to the first dose of trial treatment; Immunotherapy or biological therapy, or investigational agent within weeks (Note: Some cohort exceptions allow anti-PD- therapy) Chemotherapy, immunotherapy (including interferon), or biological therapy, radiation therapy and/or surgery within weeks prior to first dose of study drug. Patients must be >= weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents; or at least half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation Patient who has had chemotherapy, radiation, or biological cancer therapy within days prior to the first dose of study drug Treatment with chemotherapy, monoclonal antibodies or biological agents (e.g. ibrutinib, lenalidomide) within days prior to entering the study Discontinuation of all prior chemotherapy, immunotherapy, or biological therapy at least weeks prior to the first dose of investigational product is required. Patients who have had prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, and any investigational agents within days of starting study treatment (not including palliative radiotherapy at focal sites), or corticosteroids that are prohibited per protocol within days of starting study treatment Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Patients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiation therapy and biological therapy) while taking study medication; however, patients receiving CDK/ inhibitor ormTOR inhibitor as a standard of care while on study is permitted Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy Concomitant antineoplastic therapies including chemotherapy, radiotherapy, or biological agents during the study At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy Patients must have recovered to =< grade toxicity (except alopecia and hearing loss) from any prior chemotherapy, other investigational therapy, hormonal, biological, targeted agents Any of following for the treatment of cancer within weeks of first study treatment: chemotherapy, immunotherapy, experimental therapy or biological therapy Anti-neoplastic treatment for KS (including chemotherapy, radiation therapy, local therapy including topical fluorouracil [-FU], biological therapy, or investigational therapy) within four weeks of enrollment At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy Patients who have received chemotherapy, biological agents or investigational therapy within weeks prior to entering the study Chemotherapy, biological therapy or investigational agents (except EGFR TKIs) within weeks Treatment with an unapproved, investigational therapeutic agent, immunotherapy or biological therapy within days prior to the first dose of study drug Receipt of any biological therapy within weeks of the first dose of GSK Received prior investigational or non-investigational cytotoxic chemotherapy, hormonal therapy, biological therapy (including but not limited to monoclonal antibodies, small molecules or other immunotherapy) to treat hepatocellular carcinoma. Actively receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Patients with metastatic cancers who are considering or pursuing additional palliative therapy after progressing on at least two prior lines of chemotherapy, immunotherapy, biological or targeted therapies Undergone cancer treatment (excluding hormonal therapy or biological maintenance therapy) in the weeks prior to enrollment Received a therapeutic intervention with at least one of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy (any modality) Have had palliative radiation or biological cancer therapy within weeks prior to the first dose of study drug Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least weeks, and no more than months and weeks, prior to enrollment and must be in complete remission; consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy (chemo) or biological therapy Are currently undergoing treatment for cancer with chemotherapy, hormone therapy, radiation, or biological therapy Chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within days Patients already scheduled to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression) At the time of enrollment, patients may not have received any biological, chemotherapy, or radiation therapy Concurrent treatment with chemotherapy, molecule-selective, biological, or radiotherapeutic agent Subject must not have received any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic pancreatic adenocarcinoma, with the following exceptions and notes: Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biological therapy) other than the ones specified in the protocol; any other investigational drugs should be discontinued weeks prior to the first dose of study medication Has had chemotherapy, radiation, biological cancer therapy or major surgery within weeks prior to the first dose of study treatment Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, and any investigational agents within days of starting study treatment (not including palliative radiotherapy at focal sites) Patients who have been treated with chemotherapy, with biological therapy or other investigational agent must have discontinued the treatment at least weeks ( days) prior to starting the study drug on Study Day -